Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies

Gelpi, Rosana; Rodríguez‐Villar, C.; Paredes, David; Roque, Rebeca; Ruíz, Ángel; Adàlia, R.; Sousa, Emanuel A.; Revuelta, Ignacio; Solé, Mar; Martínez-Priego, Llúcia; Navarro, Mireia; Lens, Sabela; Oppenheimer, Federico; Diekmann, Fritz

doi:10.1111/tri.13270

Cited by 3 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 88%

“…In the 11 donors with a positive plasma load, investigators detected viral RNA by RT-PCR in 16 of the 22 kidneys (72.7%), data similar to ours. However, in the remaining three donors with a negative plasma load, none of the six grafts showed viral RNA, in keeping with Gelpi’s results [ 17 ]. Compared to our study, Shike et al’s [ 13 ] has the advantage of having a large amount of tissue on which the virus could be detected, since it included kidneys rejected for transplantation instead of on graft cylinders for transplantation.…”

Section: Discussionsupporting

confidence: 86%

“…Gelpi et al [17] reported an experience similar to ours, but with different and perhaps complementary results. These authors ruled out the presence of occult HCV infection by kidney graft biopsy in three seronegative recipients who had not taken DAA when receiving the transplant from seropositive, non-viremic donors.…”

Section: Discussionsupporting

confidence: 72%

See 2 more Smart Citations

Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series

Franco,

Gosalvez,

Gimeno

et al. 2023

Transpl Int

View full text Add to dashboard Cite

The transmission of hepatitis C virus from viremic donors to seronegative recipients of kidney transplantation is well documented. Pre-transplant administration of direct-acting antivirals prevents viremia, but the seroconversion rate is high. We studied the transmission of the virus through the transplanted tissue by determining viral RNA in 15 kidneys from 8 deceased viremic donors, 5 males and 3 females aged 52.3 ± 15 years. HIV positive donors and active intravenous drugs abusers were discarded to avoid possible window periods in the virus transmission. Recipients, 9 males and 6 females aged 52.7 ± 18 years, were treated with glecaprevir/pibrentasvir for 8 weeks and received immunosuppression with thymoglobulin, tacrolimus, sirolimus and prednisone. Hepatitis C Virus was detected in 9 of the 15 histological samples analyzed but viremia was detected in no recipient at day 1 and 7 post–transplantation and 12 weeks after the treatment. However, 13 of the 15 recipients had seroconverted within 1 month. In conclusion, Hepatitis C virus was detected in a significant proportion of tissue of kidney grafts from viremic donors, but treatment with direct-acting antivirals avoids the transmission of the virus from donor to recipient. Then Donor pools should be expanded.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series

Franco,

Gosalvez,

Gimeno

et al. 2023

Transpl Int

View full text Add to dashboard Cite

show abstract

“…Conversely, as we have previously reported, there is a lack of evidence of occult HCV infection after kidney transplantation in patients who had spontaneous HCV clearance or after interferon therapy before transplantation while on dialysis . Similarly, occult HCV infection was not described in negative HCV kidney transplant recipients that received positive HCV‐treated donors . Recently, it has been suggested that occult HCV infection might be responsible for the persistence of liver test abnormalities in liver transplant recipients who have achieved SVR after DAA treatment .…”

Section: Introductionmentioning

confidence: 62%

No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

Bello

Abravanel

Alric³

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Background and Aims: It has been recently suggested that occult hepatitis C virus (HCV) infection and hepatitis E virus (HEV) reactivation might occur after direct acting antiviral agent-induced (DAA-induced) sustained virological response (SVR). The aim of our study was to identify occult HCV and HEV infection in a cohort of organ transplant patients who had achieved SVR and had persistent elevation in liver-enzyme levels. Patients and Method: Sixty-six liver and/or kidney transplant patients were treated with DAAs. All but one achieved SVR12. Twenty-nine (8-39) months post-SVR12, 8 of the 65 patients (12.3%) who achieved SVR12 had persistently elevated liver enzyme levels. In 1 patient, this was related to hepatitis B virus reactivation. In the 7 remaining patients, blood samples (n = 7), liver biopsies (n = 4), and peripheral blood mononuclear cells (PBMCs) (n = 7) were collected simultaneously in order to identify occult HCV or HEV infection.Results: Hepatitis C virus RNA and HEV RNA were not detected in serum, liver tissues, or PBMCs. No HEV reactivation was observed after HCV clearance in patients who had anti-HEV IgG. Conclusion:Our study suggests that there is no occult HCV or HEV infection in transplant patients after successful treatment of HCV infection with DAAs, even in patients with a persistent elevation of liver enzyme levels. However, due to the small number of patients included in our study, this finding should be confirmed in a larger cohort. K E Y W O R D Sdirect acting antiviral agents, hepatitis C virus, hepatitis E virus, kidney transplantation, liver transplantation, occult infection, ribavirin

show abstract

Pathological Consequences in Anti-HCV Antibody-Positive Organ Donation to an Anti-HCV Antibody-Negative Recipient

Rossetto,

Adani,

Baccarani

et al. 2024

Transplantation Proceedings

View full text Add to dashboard Cite

Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies

Cited by 3 publications

References 7 publications

Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series

Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series

No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

Pathological Consequences in Anti-HCV Antibody-Positive Organ Donation to an Anti-HCV Antibody-Negative Recipient

Contact Info

Product

Resources

About